Survodutide Research Peptide — Scientific Overview
Survodutide (BI 456906) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor (GCGR) agonist developed by Boehringer Ingelheim. Unlike purely GLP-1R-focused peptides, Survodutide simultaneously activates both GLP-1R (for insulin secretion, satiety, and glucose regulation) and GCGR (for hepatic fat mobilization, increased energy expenditure, and thermogenesis). This dual mechanism makes it particularly relevant for research into non-alcoholic fatty liver disease/MASH, where hepatic fat reduction is a primary endpoint.
Survodutide (BI 456906) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor (GCGR) agonist developed by Boehringer Ingelheim. Unlike purely GLP-1R-focused peptides, Survodutide simultaneously activates both GLP-1R (for insulin secretion, satiety, and glucose regulation) and GCGR (for hepatic fat mobilization, increased energy expenditure, and thermogenesis). This dual mechanism makes it particularly relevant for research into non-alcoholic fatty liver disease/MASH, where hepatic fat reduction is a primary endpoint. Phase II data for Survodutide has been presented in obesity and MASH indications. In Phase II obesity trials, Survodutide showed significant weight loss compared to placebo. In Phase II MASH trials (NCT04771273), liver fat content reduction and improvements in histological endpoints were observed. Boehringer Ingelheim is advancing Survodutide in Phase III trials for both obesity and MASH. The compound’s strong hepatic activity (from GCGR) alongside GLP-1R mediated benefits makes it a unique research tool for liver metabolism studies.
Research Background
Phase II data for Survodutide has been presented in obesity and MASH indications. In Phase II obesity trials, Survodutide showed significant weight loss compared to placebo. In Phase II MASH trials (NCT04771273), liver fat content reduction and improvements in histological endpoints were observed. Boehringer Ingelheim is advancing Survodutide in Phase III trials for both obesity and MASH. The compound’s strong hepatic activity (from GCGR) alongside GLP-1R mediated benefits makes it a unique research tool for liver metabolism studies.
Key Research Areas
- GLP-1/Glucagon Dual Agonism Research: Simultaneous GLP-1R and GCGR pathway activation and downstream signaling
- MASH/NAFLD Research: Hepatic steatosis, fibrosis, and steatohepatitis endpoint studies
- Obesity Research: Energy balance and body weight reduction in metabolic models
- Hepatic Lipid Research: Liver fat content reduction and hepatic lipid metabolism
- Metabolic Research: Glucose metabolism, insulin sensitivity, and glycemic homeostasis
- Energy Expenditure Research: Glucagon-mediated thermogenesis and fat oxidation studies
Technical Specifications
| Parameter | Value |
|---|---|
| Classification | Dual GLP-1/Glucagon receptor agonist (BI 456906) |
| Developer | Boehringer Ingelheim |
| Purity | ≥98% (HPLC-verified) |
| Form | Lyophilized powder, sealed under argon |
| Storage | −20°C (long-term) |
| Documentation | Batch-specific COA (HPLC + Mass Spec) |
Storage & Handling (Research Laboratories)
Lyophilized Survodutide should be stored at −20°C for long-term preservation, protected from light and moisture. For short-term active research use, 4°C storage is acceptable for up to approximately 4 weeks. Minimize repeated freeze-thaw cycles. Follow standard laboratory peptide reconstitution and handling protocols for all experimental use.
